The US Food and Drug Administration is asking its external advisors to weigh the uncertainty of pediatric efficacy data for Avillion LLP’s novel, fixed-dose combination of budesonide and albuterol sulfate for asthma.
Efficacy of the budesonide/albuterol (BDA) combination (also known as PT027) was demonstrated in the overall population of the Phase III...





